Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)

被引：1
|
作者：
Ando, M., Sr.
Yonemori, K.
Yunokawa, M.
Nakano, E.
Kouno, T.
Shimizu, C.
Katsumata, N.
Tamura, K.
Arioka, H.
Fujiwara, Y.
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Yokohama Ind Accid Hosp, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)
    Laack, Eckart
    Thoem, Ina
    Kruell, Andreas
    Engel-Riedel, Walburga
    Mueller, Thomas
    Meissner, Christoph
    Duerk, Heinz
    Fischer, Juergen
    Guetz, Sylvia
    Kortsik, Cornelius
    Elbers, Matthias
    Schuch, Gunter
    Andritzkya, Birte
    Goern, Michael
    Burkholder, Iris
    Edler, Lutz
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    LUNG CANCER, 2007, 57 (02) : 181 - 186
  • [2] Phase II study of carboplatin and irinotecan (CPT-11) in patients with limited disease small cell lung cancer (SCLC)
    Laack, E.
    Boeters, I.
    Kruell, A.
    Engel-Riedel, W.
    Mueller, T.
    Meibner, R.
    Duerk, H.
    Burkholder, I.
    Hossfeld, D. K.
    Bokemeyer, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 328 - 328
  • [3] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [4] Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial
    Holtan, S. G.
    Foster, N. R.
    Erlichman, C. E.
    Aubry, M.
    Ames, M. M.
    Safgren, S.
    Steen, P. D.
    Morton, R. F.
    Graham, D.
    Goetz, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Sawaki, A
    Ohkawa, S
    Ishikawa, O
    Saitoh, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [6] A phase II study of irinotecan (CPT-11) and carboplatin in patients with previously untreated small cell lung cancer (SCLC):: Preliminary results.
    Amenedo, M
    Vázquez, F
    Lázaro, M
    Casal, J
    Mel, JR
    Antón, LM
    Firvida, JL
    Grande, C
    Castellanos, J
    Balcells, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
  • [7] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [8] Irinotecan (CPT-11) metabolism and disposition in cancer patients
    Sparreboom, A
    de Jonge, MJA
    de Bruijn, P
    Brouwer, E
    Nooter, K
    Loos, WJ
    van Alphen, RJ
    Mathijssen, RHJ
    Stoter, G
    Verweij, J
    CLINICAL CANCER RESEARCH, 1998, 4 (11) : 2747 - 2754
  • [9] A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
    Irvin, WP
    Price, FV
    Bailey, H
    Gelder, M
    Rosenbluth, R
    Durivage, HJ
    Potkul, RK
    CANCER, 1998, 82 (02) : 328 - 333
  • [10] A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer.
    Kurata, T
    Kaneda, H
    Tamura, K
    Satoh, T
    Nogami, T
    Uejima, H
    Nakagawa, K
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 703S - 703S
12345